Abstract:Objective- Despite the high clinical relevance of thrombolysis, models for its study in human flowing blood are lacking. Our objective was to develop a microfluidic model for comparative evaluation of thrombolytic therapeutic strategies. Approach and Results- Citrated human blood was supplemented with 3,3'-dihexyloxacarbocyanine iodide and Alexa Fluor 647 fibrinogen conjugate, recalcified, and perfused for 3 to 4 minutes at venous or arterial wall shear rate in microfluidic flow chambers coated with collagen and tissue factor to generate nonocclusive fluorescent thrombi. A second perfusion was performed for 10 minutes with rhodamine-6G-labeled citrated whole blood, supplemented or not with r-tPA (recombinant tissue-type plasminogen activator), fluorescein isothiocyanate-conjugated r-tPA, and Alexa Fluor 568 plasminogen conjugate. Plasminogen and r-tPA bound to preformed thrombi and r-tPA caused a concentration-dependent decrease in thrombus fibrin content (up to 50% reduction at 15 μg/mL r-tPA) as assessed by fluorescence microscopy. Fibrinolysis was confirmed by measurement of D-dimers in the output flow. Remarkably, despite ongoing fibrinolysis, new platelets continued to be recruited to the thrombus under lysis. Under the arterial condition, combining r-tPA with hirudin enhanced fibrinolysis but did not prevent the recruitment of new platelets, which was, however, prevented by antiplatelet agents (ticagrelor or the GPVI [glycoprotein VI]-blocking antigen-binding fragment 9O12). Conclusions- Our microfluidic thrombolysis model is suitable for studying thrombolysis and testing the efficacy of drugs used in combination with r-tPA. Real-time analysis of fibrin and platelets during r-tPA-mediated fibrinolysis at arterial or venous flow conditions showed that platelets continue to accumulate during fibrinolysis. Such platelet accumulation may impair r-tPA-mediated recanalization.

Label-free multimodal quantitative imaging flow assay for intrathrombus formation in vitro

A microfluidic hemostatic diagnostics platform: Harnessing coagulation-induced adaptive-bubble behavioral perception

Quantitative image analysis of thrombus formation in microfluidic in-vitro models

Label Free Monitoring of Megakaryocytic Development and Proplatelet Formation in Vitro

Investigating clot-flow interactions by integrating intravital imaging with in silico modeling for analysis of flow, transport, and hemodynamic forces

In microfluidico: Recreating in vivo hemodynamics using miniaturized devices.

Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders

Tortuosity-powered microfluidic device for assessment of thrombosis and antithrombotic therapy in whole blood

Functional Platelet Aggregation Analysis Using Digital Optofluidic Scattering Quantitation

In Vivo Real-Time Red Blood Cell Migration and Microcirculation Flow Synergy Imaging-Surveyed Thrombolytic Therapy with Iron-Oxide Complexes

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model

Integration of fluorescence and MALDI imaging for microfluidic chip-based screening of potential thrombin inhibitors from natural products

High-throughput Label-Free Detection of Aggregate Platelets with Optofluidic Time-Stretch Microscopy (conference Presentation)

High-throughput measurement of human platelet aggregation under flow: application in hemostasis and beyond

Microfluidic assessment of functional culture-derived platelets in human thrombi under flow

Microclot array elastometry for integrated measurement of thrombus formation and clot biomechanics under fluid shear

Multiparameter microfluidics assay of thrombus formation reveals increased sensitivity to contraction and antiplatelet agents at physiological temperature

Quantitative Phase Imaging Characterization of Tumor-Associated Blood Vessel Formation on a Chip

Multilayer microfluidic platform for the study of luminal, transmural, and interstitial flow

Microfluidic Modeling of Thrombolysis.